Szpital Uniwersytecki W Krakowie

The medical center is at the forefront of research in neurodegenerative diseases, focusing on conditions such as Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). The center's work is pivotal in understanding the progression and management of these complex disorders.

• Alzheimer’s Disease Research
• Mild Cognitive Impairment Studies
• Neuroprotective Strategies

Through innovative clinical trials, the center contributes significantly to the development of new therapeutic approaches aimed at improving patient outcomes and quality of life.

Specializing in the study of pharmacokinetics (PK) and pharmacodynamics (PD), the center is dedicated to understanding how drugs interact with the body and their effects on disease progression. This research is crucial for optimizing treatment regimens and enhancing drug efficacy.

• Drug Metabolism and Distribution
• Therapeutic Drug Monitoring
• Individualized Medicine

The center's expertise in PK and PD studies supports the development of personalized medicine approaches, ensuring that treatments are tailored to individual patient needs.

Focusing on clinical safety and tolerability, the center conducts comprehensive assessments of new therapeutic agents. This research is essential for identifying potential adverse effects and ensuring patient safety in clinical settings.

• Adverse Event Monitoring
• Risk-Benefit Analysis
• Patient-Centric Safety Protocols

By prioritizing safety and tolerability, the center plays a critical role in advancing safe and effective treatments for patients with neurodegenerative diseases.